**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 54385

**Manuscript Type:** CASE REPORT

L**iver cirrhosis in a child associated with Castleman's disease: A case report**

Kobayashi S *et al.* Liver cirrhosis associated with Castleman's disease

Soya Kobayashi, Ayano Inui, Tomoyuki Tsunoda, Syuichiro Umetsu, Tsuyoshi Sogo, Masaaki Mori, Masato Shinkai, Tomoo Fujisawa

**Soya Kobayashi, Ayano Inui, Tomoyuki Tsunoda, Syuichiro Umetsu, Tsuyoshi Sogo, Tomoo Fujisawa**, Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohama City Tobu Hospital, Yokohama 230-8765, Japan

**Masaaki Mori**, Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan

**Masato Shinkai**, Department of Surgery, Kanagawa Children’s Medical Center, Yokohama 232-8555, Japan

**Author contributions:** Kobayashi S and Inui A designed the report; Kobayashi S collected the patient’s clinical data; Tsunoda T, Umetsu S, Sogo T, Mori M and Fujisawa T participated in study design; Kobayashi S and Inui A analyzed the data and wrote the paper; Shinkai M performed a lymph node biopsy; all authors have finally approved the version of the article to be published.

**Corresponding author:** **Ayano Inui, MD, PhD, Director,** Department of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohama City Tobu Hospital, 3-6-1 Shimosueyoshi, Tsurumi-ku, Yokohama 230-8765, Japan. a\_inui@tobu.saiseikai.or.jp

**Received:** January 30, 2020

**Revised:** March 27, 2020

**Accepted:** April 21, 2020

**Published online:** May 6, 2020

**Abstract**

BACKGROUND

Castleman's disease (CD) is a lymphoproliferative disorder. TAFRO syndrome is classified as a variant of CD based on its key clinical manifestations of thrombocytopenia, anasarca (generalized edema and pleural effusion), fever (pyrexia), reticulin fibrosis in the bone marrow and the proliferation of megakaryocytes, and organomegaly (such as hepatosplenomegaly and multiple lymphadenopathies); TAFRO syndrome is mainly reported in Japanese patients. To our knowledge, this is the first pediatric case report detailing a CD-associated disorder progressing to cirrhosis.

CASE SUMMARY

A 10-year old male patient presented with fever and anemia. Six months before hospitalization, he had remarkable abdominal distention. Subsequently, he visited a clinic for a fever that lasted 5 d. The physical findings were marked hepatosplenomegaly and cervical lymphadenopathy. A blood test revealed leukocytosis, microcytic anemia, aspartate aminotransferase-dominant transaminase elevation, high levels of C-reactive protein, polyclonal hypergammaglobulinemia, and high levels of interleukin-6 and vascular endothelial growth factor. Abdominal contrast computed tomography and magnetic resonance imaging suggested cirrhosis, which was confirmed by liver histology. Histological findings in the enlarged hepatic lymph nodes revealed both hyperplasia and atrophy of lymphoid follicles with some vascular hyperplasia and moderate plasmacytosis between the lymphoid follicles, which is compatible with lymph node histology in TAFRO syndrome. Prednisolone was not effective in reducing the patient’s symptoms; therefore, the patient was prescribed tocilizumab. To date, the patient remains free of fever and continues to receive tocilizumab.

CONCLUSION

We described the clinicopathological features of TAFRO syndrome to highlight the clinical presentation of this rare disease in a pediatric case.

**Key words:** Castleman disease; Case report; Multi-centric Castleman’s disease; Liver cirrhosis; Tocilizumab; Child

Kobayashi S, Inui A, Tsunoda T, Umetsu S, Sogo T, Mori M, Shinkai M, Fujisawa T. Liver cirrhosis in a child associated with Castleman's disease: A case report. *World J Clin Cases* 2020; 8(9): 1656-1665 URL: https://www.wjgnet.com/2307-8960/full/v8/i9/1656.htm DOI: <https://dx.doi.org/10.12998/wjcc.v8.i9.1656>

**Core tip:** Castleman disease (CD) is a lymphoproliferative disorder of unknown cause. TAFRO syndrome is classified as a variant of CD based on its key clinical manifestations of thrombocytopenia, anasarca (generalized edema and pleural effusion), fever (pyrexia), reticulin fibrosis (reticulin fibrosis in the bone marrow and the proliferation of megakaryocytes), and organomegaly (*e.g.*, hepatosplenomegaly and multiple lymphadenopathies). To our knowledge, this is the first pediatric case report detailing a CD-associated disorder progressing to cirrhosis.

**INTRODUCTION**

Castleman's disease (CD) is a lymphoproliferative disorder with an unknown cause, classified into unicentric (unicentric distribution of the disease) and multicentric (multicentric distribution of the disease) types. While in Western countries, the human herpesvirus 8 (HHV-8) infection-related multicentric CD is common[1,2], majority of the CD cases in Japan are idiopathic[3,4]. The clinical features include anemia, multiple lymphadenopathy, increased inflammatory response, polyclonal hypergammaglobulinemia, and thrombocythemia. Histologically, the hyaline vascular type (HV type) is common in the unicentric type, and multicentric types are further classified into plasma cell type (PC-type) and mixed-type[5]. Patients with the mixed-type idiopathic multicentric Castleman’s disease (MCD), characterized by thrombocytopenia, anasarca (generalized edema and pleural effusion), fever (pyrexia), reticulin fibrosis in the bone marrow and the proliferation of megakaryocytes, and organomegaly (such as hepatosplenomegaly and multiple lymphadenopathies), are considered to have TAFRO syndrome (thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly) and often follow a more severe course[6]. There are no case reports of children with CD or TAFRO syndrome who subsequently develop cirrhosis. We presented this pediatric case to expand our understanding of this disease.

**CASE PRESENTATION**

***Chief complaints***

A 10-year-old Japanese boy presented with fever and anemia.

***History of present illness***

Six months before his hospitalization, the patient experienced remarkable abdominal distention. Subsequently, he visited a clinic for fever that persisted for 5 d. His blood test results were as follows: white blood cell 13.2 × 103/μL (white blood cell normal range: 3.5 × 103/µL-8.5 × 103/µL), hemoglobin 9.8 g/dL (hemoglobin normal range: 11.5-15.0 g/dL), and C-reactive protein (CRP) 8.6 mg/dL (CRP normal range: 0.03 mg/dL or less). Therefore, he was referred to our hospital.

***Past illness and family history***

His family history did not reveal anything of significance to his present condition. He was diagnosed with Kawasaki disease when he was 1 year old and treated with intravenous immunoglobulin therapy and antiplatelet drugs. He had a fever of unknown origin when he was 7 years old.

***Physical examination***

His physical examination revealed no growth disorder. His height and weight were 141.0 cm (± 1.0 SD) and 34.5 kg (± 0.0 SD), respectively. His body temperature was 36.3 °C. Redness of the pharynx and bleeding spots in the soft palate were observed, and his lymph nodes were palpable in the cervical region. The patient’s abdomen was slightly distended. Upon investigation, his liver was palpable 10 cm below the right costal margin and his spleen 6 cm below the left costal margin.

***Laboratory examinations***

Laboratory examinations were performed and are summarized in Table 1. A blood test revealed neutrophil-dominant leukocytosis, microcytic hypochromic anemia, elevation of aspartate aminotransferase (AST)-dominant transaminase, high CRP, polyclonal hypergammaglobulinemia, and high interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF).

***Imaging examinations***

Abdominal ultrasound revealed a rough texture of the liver. Abdominal contrast computed tomography (CT) detected hepatosplenomegaly and heterogeneous reduction of the density of the liver, suggesting advanced cirrhosis. Multiple lymphadenopathies were found in the hepatic portal, and the mesenteric and celiac arteries. A small number of ascites was observed in the pelvis (Figure 1). Multiple nodules were observed in the liver. However, the abdominal enhanced magnetic resonance imaging (MRI) did not show washout of the contrast agent in the nodules during the late phase of the contrast enhancement, which suggested regenerative nodules (Figure 2).

***Further diagnostic work-up***

Upon bone marrow examination, no monoclonal cell proliferation was observed. In positron emission tomography with CT, the standardized uptake values for the right hepatic lobe, hepatic portal, and intestinal membrane were about 2.0-3.0. Upper gastrointestinal endoscopy revealed esophageal varices. Liver histology showed sinusoidal dilation in the hepatic lobule, significant inflammatory cell infiltration, bile ductular proliferation, and fibrotic expansion in portal areas (Figure 3). When testing for high serum immunoglobulin G4 (IgG4) levels (191 mg/dL), a special immunohistological staining of the liver tissue was negative for IgG4. Endoscopic retrograde cholangiopancreatography showed no evidence of sclerosing cholangitis, leading to the negative diagnosis of Langerhans cell histiocytosis- or immunodeficiency-related sclerosing cholangitis. Intraoperative findings from laparoscopy revealed roughness of the liver surface, suggesting liver cirrhosis (Figure 4). Laparoscopic lymph node biopsy revealed both hyperplasia and atrophy of lymphoid follicles, lymphoid proliferation with some vascular hyperplasia, and moderate interfollicular plasmacytosis (Figure 5).

**FINAL DIAGNOSIS**

Based on the abovementioned findings, the final diagnosis was CD-associated disease.

**TREATMENT AND OUTCOME**

According to the treatment regimen for CD, 1 mg/kg per day of prednisolone (PSL) was administered for 4 wk. However, there was no improvement in fever and serum CRP. Finally, the patient was switched from PSL to 8 mg/kg per day of tocilizumab, and the fever subsided.

**DISCUSSION**

CD is a rare lymphoproliferative disorder first reported by Castleman *et al*[7] in 1956. To date, there has been no epidemiological study of the disease in children. However, a study conducted in the United States estimated the annual incidence of CD to be 0.24 per million[8]. A study conducted in Japan estimated the prevalence and annual incidence to be approximately 1500 and 1 per million, respectively[9]. Regarding pathological types, the syndrome can be classified into hyaline-vascular type (HV-type), plasma cell type (PC-type), and mixed type. Regarding clinical characteristics, CD can be roughly classified into single (localized) and multiple (systemic). Lymphadenopathy is most frequently observed in the mediastinum, while rare in the hepatic portal region[10]. The close relationship of MCD with HIV and HHV-8 has been emphasized in Western countries[1,2]. However, the relationship is seldom mentioned in studies conducted in Japan[3,4]. Fajgenbaum et al. reported HHV-8-negative MCD as idiopathic MCD (iMCD)[11]. In Japan, most patients with MCD are classified as having iMCD. In 2010, Takai et al. named the TAFRO syndrome[6] based on its key clinical manifestations of thrombocytopenia, anasarca (generalized edema and pleural effusion), fever (pyrexia), reticulin fibrosis (reticulin fibrosis in the bone marrow and the proliferation of megakaryocytes), and organomegaly (*e.g.*, hepatosplenomegaly and multiple lymphadenopathies). The histology of lymph nodes in patients with TAFRO syndrome revealed CD-like (*i.e.*, mixed-type or HV-type) characteristics. Therefore, some researchers classify TAFRO syndrome, which is rare in western regions, as a type of MCD. In most cases, patients with TAFRO syndrome have increased gamma globulin levels, decreased platelet levels, smaller lymph nodes, and significant subacute development of pleural effusion and edema, and follow a progressive (sometimes lethal) course[12,13].

In the present case, the findings from the histopathological examination of the lymph node biopsy, which was performed by a pathologist, Dr. Kojima, a member of the Castleman disease, TAFRO, and related disease research group, indicated a diagnosis of TAFRO syndrome. However, despite the presence of mild ascites, no renal dysfunction, reticulin fibrosis in the bone marrow, general anemia, or thrombocytopenia (100000/μL) were found at the first visit. Thus, the symptomology did not meet the diagnostic criteria for TAFRO syndrome. In addition, the patient had intermittent fever, but he was in good general condition. The patient not presenting with all the symptoms of the TAFRO syndrome might be because he has been receiving treatment early in the disease process due to early diagnosis. Marked hepatosplenomegaly and cirrhosis were particularly dominant in this case. There are 8 case reports of patients with MCD or TAFRO syndrome complicated by hepatobiliary disorders[14-20] (Table 2). Case reports by Baruch *et al*[14] included the description of cirrhosis in patients with Budd-Chiari syndrome. On the other hand, a study has reported diffuse liver fibrosis, cholangitis, and nodular regenerative hyperplasia (NRH)[17], suggesting that liver disease is associated with MCD and related diseases.

The pathogenesis may be explained by the overproduction of IL-6 by the germinal center of the lymph nodes. The detailed mechanisms of MCD and TAFRO syndrome are unknown. However, some patients respond to tocilizumab (humanized anti-human IL-6 receptor monoclonal antibody), suggesting that IL-6 is involved[21,22]. The overproduction of IL-6 promotes differentiation into plasma cells, which in turn produce VEGF and bind to hepatocyte receptors, promoting endothelial permeability and neovascularization. Hypoxia due to blood vessel remodeling, impaired blood flow, and imbalance between demand and supply of oxygen promotes collagen synthesis[23-25] and leads to fibrosis, suggesting that there is a relationship between VEGF and fibrosis.

**CONCLUSION**

CD associated disorder should be suspected in patients with fever of unknown origin, hepatosplenomegaly, lymphadenopathy, or polyclonal hypergammaglobulinemia. To date, there is no detailed study of liver pathology in patients with CD-associated disorder. Further understanding of CD-associated disorder may help clarify the mechanism of CD.

**ACKNOWLEDGEMENTS**

Kazuyuki Yoshizaki, Department of Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan. Masaru Kojima, Department of Diagnostic Pathology, Dokkyo Medical University School of Medicine, Tochigi, Japan.

**REFERENCES**

1 **Cesarman E**, Knowles DM. The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. *Semin Cancer Biol* 1999; **9**: 165-174 [PMID: 10343068 DOI: 10.1006/scbi.1998.0118]

2 **Dupin N**, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA, Isaacson PG, Boshoff C. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. *Blood* 2000; **95**: 1406-1412 [PMID: 10666218 DOI: 10.1046/j.1537-2995.2000.40030389.x]

3 **Suda T**, Katano H, Delsol G, Kakiuchi C, Nakamura T, Shiota M, Sata T, Higashihara M, Mori S. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. *Pathol Int* 2001; **51**: 671-679 [PMID: 11696169 DOI: 10.1046/j.1440-1827.2001.01266.x]

4 **Kojima M**, Nakamura N, Tsukamoto N, Otuski Y, Shimizu K, Itoh H, Kobayashi S, Kobayashi H, Murase T, Masawa N, Kashimura M, Nakamura S. Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. *Int J Surg Pathol* 2008; **16**: 391-398 [PMID: 18499694 DOI: 10.1177/1066896908315812]

5 **Cronin DM**, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. *Adv Anat Pathol* 2009; **16**: 236-246 [PMID: 19546611 DOI: 10.1097/PAP.0b013e3181a9d4d3]

6 **Takai K**, Nikkuni K, Shibuya H, Hashidate H. [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. *Rinsho Ketsueki* 2010; **51**: 320-325 [PMID: 20534952 DOI: 10.11406/rinketsu.51.320]

7 **Castleman B**, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. *Cancer* 1956; **9**: 822-830 [PMID: 13356266 DOI: 10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4]

8 **Robinson D Jr**, Reynolds M, Casper C, Dispenzieri A, Vermeulen J, Payne K, Schramm J, Ristow K, Desrosiers MP, Yeomans K, Teltsch D, Swain R, Habermann TM, Rotella P, Van de Velde H. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. *Br J Haematol* 2014; **165**: 39-48 [PMID: 24387011 DOI: 10.1111/bjh.12717]

9 **Yoshizaki K**. A reference guide for management of Castleman disease. *Rinsho Ketsueki* 2017; **58**: 97-107 [PMID: 28321096 DOI: 10.11406/rinketsu.58.97]

10 **Bonekamp D**, Horton KM, Hruban RH, Fishman EK. Castleman disease: the great mimic. *Radiographics* 2011; **31**: 1793-1807 [PMID: 21997995 DOI: 10.1148/rg.316115502]

11 **Fajgenbaum DC**, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. *Blood* 2014; **123**: 2924-2933 [PMID: 24622327 DOI: 10.1182/blood-2013-12-545087]

12 **Ito S**, Tsutsumi Y, Kikuchi R, Matsuoka S, Shimoyama N. [Thrombotic microangiopathy developing subsequent to tocilizumab therapy in a patient with TAFRO syndrome]. *Rinsho Ketsueki* 2018; **59**: 2432-2437 [PMID: 30531139 DOI: 10.11406/rinketsu.59.2432]

13 **Hashimoto K**, Sano T, Honma Y, Ida M, Tominaga H, Sawada A, Abe T, Takahashi H, Shimada Y, Masaki T, Kamata M, Naito S, Aoyama T, Takeuchi Y, Akiya M, Inukai M, Nakata N. An autopsy case of TAFRO syndrome with membranoproliferative glomerulonephritis-like lesions. *CEN Case Rep* 2019; **8**: 48-54 [PMID: 30244358 DOI: 10.1007/s13730-018-0363-9]

14 **Baruch Y**, Ben-Arie Y, Kerner H, Lorber M, Best LA, Gershoni-Baruch R. Giant lymph node hyperplasia (Castleman's disease): a clinical study of eight patients. *Postgrad Med J* 1991; **67**: 366-370 [PMID: 2068030 DOI: 10.1136/pgmj.67.786.366]

15 **Molina T**, Delmer A, Le Tourneau A, Texier P, Degott C, Audoin J, Zittoun R, Diebold J. Hepatic lesions of vascular origin in multicentric Castleman's disease, plasma cell type: report of one case with peliosis hepatis and another with perisinusoidal fibrosis and nodular regenerative hyperplasia. *Pathol Res Pract* 1995; **191**: 1159-1164 [PMID: 8822119 DOI: 10.1016/s0344-0338(11)80662-x]

16 **Maloisel F**, Andrès E, Chenard MP, Ellero B, Wolf P. Treatment of hepatic relapse of multicentric Castleman's disease with transplantation. *Am J Med* 2003; **115**: 160-162 [PMID: 12893409 DOI: 10.1016/s0002-9343(03)00285-7]

17 **Kiyuna A**, Sunagawa T, Hokama A, Touyama M, Tomiyama R, Sakugawa H, Kinjo F, Saito A. Nodular regenerative hyperplasia of the liver and Castleman's disease: potential role of interleukin-6. *Dig Dis Sci* 2005; **50**: 314-316 [PMID: 15745091 DOI: 10.1007/s10620-005-1601-5]

18 **Gaduputi V**, Tariq H, Badipatla K, Ihimoyan A. Systemic Reactive Amyloidosis Associated with Castleman's Disease. *Case Rep Gastroenterol* 2013; **7**: 476-481 [PMID: 24348320 DOI: 10.1159/000356825]

19 **Nagai Y**, Ando S, Honda N, Noguchi H, Maemori M, Hayashi T, Sakai H. TAFRO syndrome showing cholangitis on liver biopsy. *Rinsho Ketsueki* 2016; **57**: 2490-2495 [PMID: 28090015 DOI: 10.11406/rinketsu.57.2490]

20 **Ueki T**, Nasuno M, Kaiume H, Hiroshima Y, Sumi M, Watanabe M, Inoue D, Masaki Y, Sato Y, Kojima M, Kobayashi H. Multicentric Castleman's disease with multiple hepatic mass lesions mimicking malignant liver tumors. *Rinsho Ketsueki* 2017; **58**: 630-636 [PMID: 28679994 DOI: 10.11406/rinketsu.58.630]

21 **Nishimoto N**, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. *Blood* 2000; **95**: 56-61 [PMID: 10607684 DOI: 10.1182/blood.V95.1.56]

22 **Sakai K**, Maeda T, Kuriyama A, Shimada N, Notohara K, Ueda Y. TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review. *Mod Rheumatol* 2018; **28**: 564-569 [PMID: 26886414 DOI: 10.3109/14397595.2015.1120389]

23 **Manotham K**, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, Kurokawa K, Fujita T, Nangaku M. Evidence of tubular hypoxia in the early phase in the remnant kidney model. *J Am Soc Nephrol* 2004; **15**: 1277-1288 [PMID: 15100368 DOI: 10.1097/01.asn.0000125614.35046.10]

24 **Varga J**, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. *J Clin Invest* 2007; **117**: 557-567 [PMID: 17332883 DOI: 10.1172/JCI31139]

25 **Orphanides C**, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism. *Kidney Int* 1997; **52**: 637-647 [PMID: 9291182 DOI: 10.1038/ki.1997.377]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient and his parents for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The fifth author accepts remuneration from "EA Pharma Co., Ltd., Otsuka Pharmaceutical Factory, Inc." The sixth author accepts remuneration from "Chugai Pharmaceutical Co., Ltd., UCB Japan Co., Ltd., CSL Behring, Abbvie Japan Co., Ltd., Japan Blood Products Organization, Ayumi Pharmaceutical Co., Nippon Kayaku Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Asahikasei Pharmaceutical Co." Other authors declare that there is no conflict of interest. Even though there is a COI to disclose as of January 2020, this will not prevent the submission from proceeding.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited Manuscript

**Peer-review started:** January 30, 2020

**First decision:** March 18, 2020

**Article in press:** April 21, 2020

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Skok P, Tian H **S-Editor:** Ma YJ **L-Editor: E-Editor:** Liu MY

**Figure Legends**

**Table 1 Laboratory findings on admission**

|  |  |
| --- | --- |
| Blood cell count | |
| WBC | 8.49 × 103/μL |
| NET% | 76.1% |
| LYP% | 19.8% |
| MONO% | 2.7% |
| EOS% | 1.3% |
| RBC | 423 × 104/μL |
| Hb | 9.5 g/dL |
| Ht | 31.2% |
| MCV | 73.8 fL |
| MCH | 22.5 pg |
| MCHC | 30.4% |
| Plt | 17 × 104/μL |
| Biochemical and immune serum examination | |
| TP | 8 g/dL |
| Alb | 3.1 g/dL |
| T-bil | 1 mg/dL |
| D-bil | 0.6 mg/dL |
| AST | 95 U/L |
| ALT | 63 U/L |
| LDH | 289 U/L |
| γ-GTP | 132 U/L |
| ALP | 3152 U/L |
| Glu | 97 mg/dL |
| BUN | 7.5 mg/dL |
| Cr | 0.39 mg/dL |
| CRP | 6.83 mg/dL |
| Fe | 24 μg/dL |
| TIBC | 299 μg/dL |
| UIBC | 286 μg/dL |
| Ferritin | 65.9 ng/mL |
| NH3 | 36 μg/dL |
| AFP | 1.3 ng/mL |
| IgG | 2265 mg/dL |
| IgG4 | 191 mg/dL |
| IgA | 469 mg/dL |
| IgM | 399 mg/dL |
| Blood coagulation examination | |
| PT ratio | 60.5% |
| APTT | 32.2 s |
| Fib | 328 mg/dL |
| FDP | 6.6 μg/mL |
| D-dimer | 2.8 μg/mL |
| Cytokine/VEGF | |
| IL-6 | 40 pg/mL |
| VEGF | 49.2 pg/mL |
| Virologic test |  |
| HIV antibody | (-) |
| HHV-8 PCR | (-) |

WBC: white blood cell; RBC: red blood cell; Hb: hemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; PLT: blood platelet; CRP: C-reactive protein; TP: total protein; ALP: albumin; Glu: glucose; BUN: blood urea nitrogen; TIBC: Total iron binding capacity; UIBC: unsaturated iron binding capacity; AFP: alpha fetoprotein; VEGF: vascular endothelial growth factor; HIV: human immunodeficiency virus; PCR: Polymerase chain reaction.

**Table 2 Patients with multicentric Castleman’s disease/TAFRO syndrome complicated by hepatobiliary diseases**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Year** | **Age/sex** | **Diagnosis** | **Type** | **Pathological findings of the liver** | **Outcome** | **Ref.** |
| 1991 | 22/F | CD | Mixed | Liver cirrhosis associated with Budd-Chiari syndrome, an underlying disease | Liver transplantation waiting for Budd-Chiari syndrome | [14] |
| 1995 | 50/M | CD | PC | Diffuse fibrosis | Death due to thrombocytopenia and massive gastrointestinal bleeding | [15] |
| 35/M | CD | PC | Cholestasis and peliosis hepatis | Unknown |
| 2003 | 54/M | CD | Mixed | Nodular cirrhosis | Perform liver transplantation and maintain remission | [16] |
| 2005 | 45/M | CD | PC | Nodular regenerative hyperplasia | PSL effective | [17] |
| 2013 | 51/M | CD | - | Liver amyloidosis | Symptoms persist even after lymph node dissection | [18] |
| 2016 | 56/M | TAFRO | Mixed | Expansion of portal area, interface hepatitis, pseudo biliary hyperplasia and cholangitis | Steroid pulse, PSL, tocilizumab, rituximab | [19] |
| 2017 | 26/F | CD | PC | Fibrosis and plasma cell infiltration | PSL effective | [20] |
| This case | 10/M | CD or TAFRO | Mixed | Portal vein area fibrosis, inflammatory cell infiltration, bile duct hyperplasia | PSL ineffective, tocilizumab improves inflammatory response |  |

CD: Castleman's disease; PC: plasma cell; PSL: prednisolone.

![写真, ブラック, ホワイト が含まれている画像

自動的に生成された説明]()

**Figure 1 Abdominal contrast computed tomography.** A and B: Arrow represents hepatic lymphadenopathy; C: A small number of ascites was observed.

**![白黒写真のコラージュ

自動的に生成された説明]()**

**Figure 2 Abdominal enhanced magnetic resonance imaging.** A and B: Multiple nodules were observed in the liver;C and D: No washout of the contrast agent in the nodules was detected in the late phase of contrast enhancement.

**![テーブル, 作品, ケーキ, チョコレート が含まれている画像

自動的に生成された説明]()**

**Figure 3 Liver histopathology.** A: Hematoxylin and eosin staining (magnification, 100 ×); Dilated sinusoids and fibrotic expansion of the portal area, as well as marked inflammatory cells infiltration, were observed;B: Masson trichrome staining (magnification, 100 ×); Fibrosis was observed in the portal area;C: CK7 staining (magnification, 100 ×); Bile duct hyperplasia was observed;D: IgG4 staining (magnification, 100 ×); IgG4 was not stained.

**![屋内, 人, 男, 食品 が含まれている画像

自動的に生成された説明]()**

**Figure 4 Intraoperative findings of porta hepatis lymph nodes.**

**写真 が含まれている画像

自動的に生成された説明**

**Figure 5 Lymph node tissue in the porta hepatis.** A: Hematoxylin and eosin staining (magnification, 40 ×); Hyperplasia and atrophy of lymphoid follicles were observed;B: Hematoxylin and eosin staining (magnification, 100 ×); Lymphoid proliferation with some vascular hyperplasia was observed;C: CD21 staining (magnification, 200 ×); Moderate plasmacytosis was observed in the lymphoid follicles.